New cocktail of three drugs shows promise for tough kidney cancers
Disease control
Recruiting now
This phase 2 study is testing whether a combination of three drugs—sasanlimab, palbociclib, and axitinib—can shrink tumors or slow the growth of advanced kidney cancer. The trial will enroll 25 adults with clear cell or translocation renal cell carcinoma that has spread. Research…
Phase: PHASE2 • Sponsor: Stephanie Berg • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC